Moderna and Merck reported on August 19, 2026, that their individualized mRNA treatment intismeran autogene—also known as intismeran, V940, or mRNA-4157—met the recurrence-free-survival and distant-metastasis-free-survival endpoints in the Phase 3 INTerpath-001 trial. The study tested intismeran with KEYTRUDA (pembrolizumab) after complete surgery for high-risk melanoma. The important catch: this is a prespecified interim, topline announcement, and the companies have not disclosed the numerical size of the benefit.
What Moderna and Merck reported from INTerpath-001
The sponsors reported a statistically significant and clinically meaningful improvement in recurrence-free survival and distant-metastasis-free survival for the combination compared with KEYTRUDA alone. Recurrence-free survival measures how long patients remain free of a return of cancer or death; distant-metastasis-free survival focuses specifically on whether cancer spreads to organs or sites away from the original tumor.
Those are meaningful trial results, but they are not the same as a complete picture of patient benefit. The announcement does not provide hazard ratios, absolute recurrence rates, subgroup results, quality-of-life findings, or mature overall-survival data. The trial is continuing, so the headline result tells us that the prespecified endpoints were met—not precisely how large, durable, or broadly distributed the advantage will prove to be.
What the trial actually compared
INTerpath-001 was a randomized, double-blind, global Phase 3 trial with placebo and active-comparator controls. It enrolled 1,137 people with completely resected stage IIB, IIC, III, or IV cutaneous melanoma. Participants were assigned in a 2:1 ratio to receive either the combination or KEYTRUDA alone.
| Trial dimension | Intismeran plus KEYTRUDA | KEYTRUDA alone |
| Treatment design | Patient-specific mRNA neoantigen therapy combined with anti-PD-1 immunotherapy | Anti-PD-1 immunotherapy alone |
| Trial population | Completely resected stage IIB–IV cutaneous melanoma | Completely resected stage IIB–IV cutaneous melanoma |
| Intismeran schedule | 1 mg every three weeks for up to nine doses | Not applicable |
| KEYTRUDA schedule | 400 mg every six weeks, up to nine cycles, for approximately one year | 400 mg every six weeks, up to nine cycles, for approximately one year |
| Reported primary endpoint | Recurrence-free survival endpoint met at the interim analysis | Comparator arm |
| Reported key secondary endpoint | Distant-metastasis-free survival endpoint met at the interim analysis | Comparator arm |
This design matters because the comparison was not against doing nothing. The experimental group received the personalized treatment on top of the same KEYTRUDA backbone used in the control group. That makes the reported result specifically about the added contribution of intismeran within this trial—not a claim that the mRNA treatment works by itself.
How a patient-specific mRNA treatment works
Intismeran is built from the mutation profile of an individual patient’s tumor. Those mutations can produce neoantigens, unusual markers that distinguish tumor cells from healthy cells. The treatment is designed to encode up to 34 patient-specific neoantigens.
In plain English, the custom mRNA acts like a temporary set of instructions. Cells use it to produce selected tumor-related targets, giving the immune system something specific to recognize. T cells can then be directed toward cells displaying those targets. KEYTRUDA adds a second piece: it blocks the PD-1 immune checkpoint, a signal that can restrain T-cell activity, helping support the antitumor immune response.
The approach is personalized in a very literal sense: the tumor’s mutation profile guides the target selection rather than every patient receiving an identical sequence.
This is treatment after surgery, not prevention
Despite the familiar word “vaccine,” intismeran is not intended to prevent melanoma from developing in healthy people. It is a therapeutic treatment designed for patients whose high-risk melanoma has already been surgically removed, with the goal of reducing the chance that the disease returns.
That distinction is crucial. “Preventing recurrence” means trying to stop residual disease from coming back after surgery; it does not mean preventing the original cancer in someone who has never had melanoma. Nor does a positive recurrence endpoint establish that the treatment cures cancer.
The number readers are still waiting for
The Phase 3 announcement establishes that the two prespecified efficacy endpoints were met, but it does not disclose the hazard ratios or absolute event rates needed to quantify the difference between the treatment arms. It also does not yet provide mature overall-survival findings—the data that would show whether patients live longer with the addition of intismeran.
There is earlier evidence, but it belongs to a different study. A five-year follow-up from an earlier Phase 2b trial reported a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death for intismeran plus KEYTRUDA compared with KEYTRUDA alone. Those figures must not be transferred to INTerpath-001. They are Phase 2b results, not the newly announced Phase 3 measurements.
The distinction may sound fussy, but it is the whole story. A late-stage trial can meet its endpoints while readers still need the effect size, confidence intervals, absolute outcomes, subgroup results, safety follow-up, and quality-of-life data to understand the treatment’s practical value.
Availability and the next steps for intismeran
Intismeran remains investigational and is not publicly available outside clinical trials in the supplied evidence. No treatment price is established here, and the Phase 3 announcement is not a commercial launch or an approval announcement.
Merck and Moderna plan to present more detailed data at an international medical meeting and discuss regulatory submissions. INTerpath-001 is also continuing for longer follow-up, including overall survival. Related individualized neoantigen studies are reported in non-small-cell lung cancer, bladder cancer, and renal cell carcinoma, but the melanoma result does not establish that the approach works in those diseases.
The bottom line is encouraging but narrower than the hype-friendly version: Moderna and Merck reported a positive Phase 3 milestone for a personalized post-surgery melanoma treatment, and the trial met two important recurrence-related endpoints. The next decisive step is seeing the numbers behind that announcement—and whether the benefit remains meaningful as follow-up matures.
